Safety of bevacizumab with fluoropyrimidine-based regimens for first-line teatment of metastatic colorectal cancer

被引：1
|
作者：
Tyagi, Preeta
Chu, Edward
机构：
来源：
CLINICAL COLORECTAL CANCER | 2006年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1533-0028(11)70281-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：189 / 191
页数：3
相关论文
共 50 条
  • [1] Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
    Whyte, S.
    Pandor, A.
    Stevenson, M.
    Rees, A.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [2] Efficacy and safety of bevacizumab with standard first-line fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer: First beat
    Rivera, F.
    Cunningham, D.
    Berry, S.
    Kretzschmar, A.
    Michael, M.
    Dibartolomeo, M.
    Mazier, M.
    Andre, N.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 17 - 17
  • [3] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study
    Hochster, Howard S.
    Hart, Lowell L.
    Ramanathan, Ramesh K.
    Childs, Barrett H.
    Hainsworth, John D.
    Cohn, Allen L.
    Wong, Lucas
    Fehrenbacher, Louis
    Abubakr, Yousif
    Saif, M. Wasif
    Schwartzberg, Lee
    Hedrick, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3523 - 3529
  • [4] Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer
    Hurwitz, H
    Kabbinavar, F
    [J]. ONCOLOGY, 2005, 69 : 17 - 24
  • [5] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    [J]. JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [6] Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.
    Hochster, H. S.
    Hart, L. L.
    Ramanathan, R. K.
    Hainsworth, J. D.
    Hedrick, E. E.
    Childs, B. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 148S - 148S
  • [7] Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer
    Grapsa, Dimitra
    Syrigos, Konstantinos
    Saif, Muhammad Wasif
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1267 - 1281
  • [8] Safety, tolerability and efficacy of the addition of bevacizumab to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer (mCRC): Results of TREE 2 cohort of the TREE study
    Hochster, H.
    Hart, L.
    Ramanathan, R. K.
    Hainsworth, J.
    Griffing, S.
    Mass, R.
    Nagarwala, Y.
    Jirau-Lucca, G.
    Shpilsky, A.
    Childs, B. H.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
  • [9] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study (vol 26, pg 3523, 2008)
    Hochster
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4697 - 4697
  • [10] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    [J]. HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
12345